ReviewBlood cancer journal2025
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.
Pralay Mukhopadhyay et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this paperpooled ittrialcites it